Related Experiment Video
Updated: Jul 20, 2026
06:36
An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices
Published on: February 5, 2015
Thymectomy and multiple sclerosis: ultrastructural study of an experimental model
V D'Andrea1, F Biancari, D Cavallotti
1Department of Surgical Sciences, University La Sapienza, Rome, Italy.
Il Giornale Di Chirurgia
|April 28, 1999
Summary
Experimental allergic encephalomyelitis (EAE) in rats causes progressive thymus damage, affecting epithelial cells and thymocytes. This suggests thymectomy as a potential therapy for multiple sclerosis.
Area of Science:
- Immunology
- Neuroscience
- Cell Biology
Background:
- Experimental allergic encephalomyelitis (EAE) is an animal model for multiple sclerosis.
- The thymus plays a crucial role in T-cell maturation and immune regulation.
Purpose of the Study:
- To investigate the ultrastructural changes in the thymus during EAE development.
- To explore the role of thymic epithelial cells and thymocytes in EAE pathogenesis.
Main Methods:
- Transmission electron microscopy was used to examine thymus specimens from rats with induced EAE.
- Histological analysis of thymic tissue.
Main Results:
- Progressive ultrastructural alterations were observed in the thymus, correlating with EAE severity.
- Degeneration of both thymic epithelial cells and thymocytes was identified as the cause of thymic disorganization.
- These changes indicate a direct involvement of thymic components in EAE.
Conclusions:
- Thymic epithelial cells and thymocytes are directly implicated in the pathogenesis of EAE.
- Thymectomy may represent a novel therapeutic strategy for managing multiple sclerosis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...